Figure 2.
Efficacy and safety profile of first generation anti-CD40L drugs (ruplizumab and toralizumab) compared with that of second generation anti-CD40L drugs (dapirolizumab pegol, letolizumab, dozadalibep, and frexalimab).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.